Harbour BioMed signs $350m deal with Kelun-Biotech for ex-China rights to A167

Image: Harbour BioMed, Kelun-Biotech to develop cancer immunotherapy A167. Photo: courtesy of dream designs/FreeDigitalPhotos.net.